Skip to main content

GlaxoSmithKline Will Use Beyond Genomics Platform

NEW YORK, Dec. 10-GlaxoSmithKline will use Beyond Genomics' systems biology platform to describe disease pathways and identify disease and drug response markers, the company said in a statement today.

 

The deal is an "evaluation agreement." Financial details and specifics of the agreement were not revealed.

 

Beyond Genomics, based in Waltham, Mass., combines proteomic and metabolomic analysis with pattern recognition and data mining software for a systems approach to drug discovery and development.

 

For further details, see the press release

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.